Ratings by Mizuho (Joseph Catanzaro)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/17/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/16/2026 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2026 | Q32 Bio Inc. | QTTB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2026 | Q32 Bio Inc. | QTTB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2026 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2026 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (N/A) |
132.55 (134.00) |
1.09% | Details | |
| 6/8/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2026 | Q32 Bio Inc. | QTTB | New Coverage | Outperform (N/A) |
5.67 (15.05) |
165.43% | Details | |
| 5/14/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Upstream Bio | UPB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2026 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
8.63 (12.70) |
47.16% | Details | |
| 4/14/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/30/2026 | Eikon Therapeutics Inc. | EIKN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Outperform (N/A) |
13.64 (9.77) |
-28.37% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2026 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
12.35 (28.56) |
131.26% | Details | |
| 1/27/2026 | Erasca Inc | ERAS | New Coverage | Outperform (N/A) |
9.96 (19.17) |
92.47% | Details | |
| 1/13/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Upstream Bio | UPB | New Coverage | Outperform (N/A) |
29.32 (7.01) |
-76.09% | Details | |
| 12/18/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Neutral (N/A) |
18.15 (27.76) |
52.95% | Details | |
| 12/18/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
32.97 (100.23) |
204% | Details | |
| 12/18/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
18.82 (19.37) |
2.92% | Details | |
| 12/11/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2025 | Nurix | NRIX | New Coverage | Outperform (N/A) |
9.84 (23.12) |
134.96% | Details | |
| 10/21/2025 | Revolution | RVMD | New Coverage | Outperform (N/A) |
54.10 (186.16) |
244.1% | Details | |
| 10/21/2025 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
26.83 (35.35) |
31.76% | Details | |
| 10/21/2025 | Apogee Therapeutics Inc | APGE | New Coverage | Outperform (N/A) |
55.15 (132.55) |
140.34% | Details | |
| 10/21/2025 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
59.83 (115.77) |
93.5% | Details |
